Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint in a Phase 2 trial, presenting implications for Sanofi who will acquire the drug following its agreement to buy the firm for $4.8 billion.
Ook interessant voor je
Reageer